Evaluating the efficacy and safety of bladder-sparing regimen with Disitamab Vedotin combined with Toripalimab and pelvic lymph node dissection in muscle-invasive bladder cancer patients: study protocol of a multicenter single-arm phase II trial - Lan, Tianhang; Zhu, Yingying; Zhong, Wenlong; Tan, Qihong; Lin, Tianxin; Huang, Jian; He, Wang (BMC cancer, 2025)
Keywords: Adult; Aged; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Apoptosis; Arm; Biological products; Bladder cancer; Bladder-sparing treatment; Cancer; Cancer patients; Cancer therapies; Care and treatment; Cell death; Cellular biology; Clinical trials; Clinical Trials, Phase II as Topic; Combination therapy; Combined Modality Therapy; Cystectomy; Disitamab Vedotin; Ethics; Female; Health aspects; Humans; Immune checkpoint inhibitors; Immunoconjugates - administration & dosage; Invasiveness; Lymph Node Excision - methods; Lymph nodes; Lymphatic system; Male; Malignancy; Medical prognosis; Metastases; Metastasis; Middle Aged; Multicenter Studies as Topic; Muscle-invasive bladder cancer (MIBC); Neoplasm Invasiveness; Oligopeptides; Oncology, Experimental; Organ Sparing Treatments - methods; Patient outcomes; Patients; Pelvic lymph node dissection (PLND); Pelvis; Preservation; Product development; Quality of life; Radiation therapy; Study Protocol; Surgery; Survival; Toripalimab; Toxicity; Transurethral bladder tumor resection (TURBT); Treatment Outcome; Urinary Bladder Neoplasms - drug therapy; Urinary Bladder Neoplasms - pathology; Urinary Bladder Neoplasms - therapy; Urological surgery; Viral antibodies; Vital signs; China; Transurethral bladder tumor resection (TURBT); Disitamab Vedotin; Muscle-invasive bladder cancer (MIBC); Toripalimab; Bladder-sparing treatment; Pelvic lymph node dissection (PLND)